Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice
Abstract
SNX-2112, a novel inhibitor of Hsp90 currently used as an anti-tumor drug, induces apoptosis in multiple tumor cell lines. It destabilizes specific client proteins, but the molecular mechanism of the apoptosis effect of SNX-2112 is poorly understood. Here, we analyzed the apoptotic effect of SNX-2112 on human chronic myeloid leukemia (CML) K562 cells. Transcriptomic and proteomic approaches further revealed that caspase signals originated from mitochondria dysfunction, mediated by Akt signaling pathway inactivity. Additionally, SNX-2112 prolonged the survival time of NOD/SCID mice inoculated with K562 tumor cells. Our results demonstrated the therapeutic potential of SNX-2112 against human CML.
Structured summary
MINT-7033976: BAD (uniprotkb:Q92934) physically interacts (MI:0218) with Bcl2-Xl (uniprotkb:Q07817) by anti bait coimmunoprecipitation (MI:0006)
Abbreviations: 17-AAG, 17-(allylamino)-17-demethoxygeldanmycin, DMSO, dimethylsulfoxide, CML, chronic myeloid leukemia, FBS, fetal bovine serum, IEF, isoelectric focusing, IPG, immobilized pH gradient, PRDX5, peroxiredoxin V, DLD, dihydrolipoamide dehydrogenase, ECH1, enoyl coenzyme A hydratase 1, IDH3A, isocitrate dehydrogenase alpha subunit, ALDH2, aldehyde dehydrogenase 2 family, NDUFV2, NADH dehydrogenase flavoprotein 2, TRAP1, tumor necrosis factor-associated protein 1, Crkl, v-crk sarcoma virus CT10 oncogene homolog (avian)-like, Grb2, growth factor receptor bound protein 2
Keywords: SNX-2112, K562 cell, Apoptosis, Transcriptomic, Proteomic, Mitochondria dysfunction
To access this article, please choose from the options below
PII: S0014-5793(09)00359-7
doi:10.1016/j.febslet.2009.04.046
© 2009 Federation of European Biochemical Societies
